Abstract: The present disclosure provides CRISPR/Cas chain reaction (CCR) systems and methods for amplifying the detection sensitivity of a primary CRISPR-based target detection (CBTD) system for detecting targets. Also described are methods of using CCR systems to amplify the detection sensitivity of primary CBTD systems to detect a target without a target preamplification step. Multiplexed CBTD systems for detecting a target using two different Cas enzyme systems are provided.

Abstract: The present disclosure relates to methods and products associated with in vitro and in vivo protease activity measurements and enzyme profiling. Some aspects of the present disclosure relate to measuring remotely triggered protease activity. In particular, the disclosure relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence or absence of active enzymes associated with disease or conditions. The disclosure also relates to products, kits, and databases for use in the methods of the disclosure.

Abstract: The present disclosure provides systems that include a CRISPR-associated (Cas) enzyme with trans cleavage activity; a guide CRISPR RNA (crRNA) including a guide sequence and a polynucleotide extension sequence, wherein the guide sequence is configured to bind to a target polynucleotide, the polynucleotide extension sequence is linked to 3?-end of the guide sequence; and a probe including an oligonucleotide element labeled with a detectable label, wherein a detectable signal or a detectable molecule is generated when the probe is cleaved by the CRISPR-associated enzyme. The present disclosure also provides modified Cas complexes having a crRNA including a guide sequence and a polynucleotide extension sequence as well as modified CRISPR-Cas complexes having a guide crRNA including a guide sequence, an optional extension sequence, a linker sequence, and a complementary sequence, such that a portion of the crRNA sequence forms a toehold conformation at the 3? end of the guide sequence.

Abstract: The present disclosure relates to methods and products associated with in vitro and in vivo protease activity measurements and enzyme profiling. Some aspects of the present disclosure relate to measuring remotely triggered protease activity. In particular, the disclosure relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence or absence of active enzymes associated with disease or conditions. The disclosure also relates to products, kits, and databases for use in the methods of the disclosure.

Abstract: The present disclosure relates to methods and products associated with in vitro and in vivo protease activity measurements and enzyme profiling. Some aspects of the present disclosure relate to measuring remotely triggered protease activity. In particular, the disclosure relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence or absence of active enzymes associated with disease or conditions. The disclosure also relates to products, kits, and databases for use in the methods of the disclosure.

Abstract: Novel photocleavable drug conjugates for forming drug depots comprise drugs attached to photocleavable groups. The drug is crosslinked via photocleavable group(s) to themselves to form a photocleavable drug conjugate that generally forms the depot.

Abstract: Novel photocleavable drug conjugates for forming drug depots comprise drugs attached to photocleavable groups. In one embodiment, the drug is linked via photocleavable group(s) to a polymer chain to form a photocleavable drug-polymer conjugate that generally forms the depot matrix. In another embodiment, the drug is crosslinked via photocleavable group(s) to themselves to form a photocleavable drug conjugate that generally forms the depot.

Abstract: Novel photocleavable drug conjugates for forming drug depots comprise drugs attached to photocleavable groups. In one embodiment, the drug is linked via photocleavable group(s) to a polymer chain to form a photocleavable drug-polymer conjugate that generally forms the depot matrix. In another embodiment, the drug is crosslinked via photocleavable group(s) to themselves to form a photocleavable drug conjugate that generally forms the depot.